Pharmaceutical composition, methods for treating and uses thereof

Abstract

The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.

1 . A method for treating and/or preventing oxidative stress, collagen deposition, vessel wall thickening, vascular stress and/or endothelial dysfunction comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to a patient in need thereof. 
     
     
         2 . The method of  claim 1 , wherein the patient is a non-diabetic patient or a type 2 or type 1 diabetes mellitus patient. 
     
     
         3 . The method of  claim 1 , wherein the method is for treating and/or preventing endothelial dysfunction in a type 2 or type 1 diabetes mellitus patient. 
     
     
         4 . A method of treating type 2 or type 1 diabetes mellitus in a patient with or at risk of oxidative stress, vascular stress and/or endothelial dysfunction, or diseases or conditions related or associated therewith,
 said method comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient.   
     
     
         5 . The method according to  claim 4 , wherein said patient has or is at risk of a cardiovascular disease. 
     
     
         6 . The method according to  claim 4 , wherein the patient has or is at risk of a cardiovascular disease selected from myocardial infarction, stroke, peripheral arterial occlusive disease. 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . A method for preventing, slowing, delaying or treating the degeneration of pancreatic beta cells and/or the decline of the functionality of pancreatic beta cells and/or for improving and/or restoring and/or stimulating and/or protecting the functionality of pancreatic beta cells and/or restoring the functionality of pancreatic insulin secretion in a patient having latent autoimmune diabetes in adults (LADA) comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient. 
     
     
         19 . The method according to  claim 18 , wherein the patient having LADA is a patient in whom one or more autoantibodies selected from GAD (GAD-65, anti-GAD), ICA, IA-2A, ZnT8 (anti-ZnT8) and IAA are present. 
     
     
         20 . A method for preserving pancreatic beta cells and/or their function in a patient having latent autoimmune diabetes in adults (LADA) comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient. 
     
     
         21 . The method according to  claim 20 , wherein the patient having LADA is a patient in whom one or more autoantibodies selected from GAD (GAD-65, anti-GAD), ICA, IA-2A, ZnT8 (anti-ZnT8) and IAA are present. 
     
     
         22 . A method for treating and/or preventing LADA (latent autoimmune diabetes of adults) in a patient, the method comprising administering empagliflozin, optionally in combination with one or more other therapeutic substances, to the patient. 
     
     
         23 . The method according to  claim 22 , wherein the patient having LADA is a patient in whom one or more autoantibodies selected from GAD (GAD-65, anti-GAD), ICA, IA-2A, ZnT8 (anti-ZnT8) and IAA are present. 
     
     
         24 . A method for reducing arterial stiffness in a patient comprising administering empagliflozin to the patient, optionally in combination with one or more other therapeutic substances, to the patient. 
     
     
         25 . The method according to  claim 1 , wherein the one or more other therapeutic substances are selected from other antidiabetic substances. 
     
     
         26 . The method according to  claim 1 , further comprising administering empagliflozin in combination with metformin, with linagliptin or with metformin and linagliptin. 
     
     
         27 . The method according to  claim 1 , wherein empagliflozin is administered orally in a total daily amount of 10 mg or 25 mg. 
     
     
         28 . The method according to  claim 1 , wherein empagliflozin is administered as a pharmaceutical composition comprising 10 mg or 25 mg of empagliflozin.